Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): A SEER-Medicare analysis. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results